JP2024537896A - アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞 - Google Patents

アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞 Download PDF

Info

Publication number
JP2024537896A
JP2024537896A JP2024522668A JP2024522668A JP2024537896A JP 2024537896 A JP2024537896 A JP 2024537896A JP 2024522668 A JP2024522668 A JP 2024522668A JP 2024522668 A JP2024522668 A JP 2024522668A JP 2024537896 A JP2024537896 A JP 2024537896A
Authority
JP
Japan
Prior art keywords
polynucleotide
cell
polynucleotide encoding
promoter
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024522668A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023069926A5 (https=
JP2024537896A5 (https=
Inventor
マイケル ゴレン、
ユ ツァオ、
アレキサンドロス ストリコウディス、
ダリャ ブラコフ、
ガン チェン、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2024537896A publication Critical patent/JP2024537896A/ja
Publication of JPWO2023069926A5 publication Critical patent/JPWO2023069926A5/ja
Publication of JP2024537896A5 publication Critical patent/JP2024537896A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2024522668A 2021-10-18 2022-10-18 アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞 Pending JP2024537896A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163256730P 2021-10-18 2021-10-18
US63/256,730 2021-10-18
PCT/US2022/078266 WO2023069926A1 (en) 2021-10-18 2022-10-18 Eukaryotic cells comprising adenovirus-associated virus polynucleotides

Publications (3)

Publication Number Publication Date
JP2024537896A true JP2024537896A (ja) 2024-10-16
JPWO2023069926A5 JPWO2023069926A5 (https=) 2025-10-24
JP2024537896A5 JP2024537896A5 (https=) 2025-10-24

Family

ID=84389146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024522668A Pending JP2024537896A (ja) 2021-10-18 2022-10-18 アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞

Country Status (11)

Country Link
US (2) US12234472B2 (https=)
EP (1) EP4419696A1 (https=)
JP (1) JP2024537896A (https=)
KR (1) KR20240099288A (https=)
CN (1) CN118103517A (https=)
AU (1) AU2022373653A1 (https=)
CA (1) CA3234939A1 (https=)
IL (1) IL312124A (https=)
MX (1) MX2024004647A (https=)
TW (1) TW202323529A (https=)
WO (1) WO2023069926A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202515999A (zh) 2023-06-20 2025-04-16 美商再生元醫藥公司 純化填充的腺相關病毒殼體之方法

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5985846A (en) 1995-06-07 1999-11-16 Baylor College Of Medicine Gene therapy for muscular dystrophy
US7232899B2 (en) 1996-09-25 2007-06-19 The Scripps Research Institute Adenovirus vectors, packaging cell lines, compositions, and methods for preparation and use
WO1998054345A1 (en) 1997-05-30 1998-12-03 Baxter International Inc. Mini-adenoviral vector
AU770005B2 (en) 1998-04-15 2004-02-12 Research Foundation Of The State University Of New York, The Selective regulation of adenovirus production
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US5989910A (en) 1998-08-03 1999-11-23 University Of Lausanne Potent genetic switch allowing regulated gene expression in eukaryotic cells
US6423544B1 (en) 1998-12-31 2002-07-23 Chiron Corporation Compositions and methods for producing recombinant virions
MY123548A (en) 1999-11-08 2006-05-31 Shell Int Research Method and system for suppressing and controlling slug flow in a multi-phase fluid stream
DE19955558C2 (de) 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US6558948B1 (en) 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
EP1362096B1 (de) 2001-02-21 2009-08-19 CEVEC Pharmaceuticals GmbH Pigmentepithelzelle des auges, ihre herstellung und verwendung in der therapie einer augen- oder zns-erkrankung
CA2485939C (en) 2002-05-29 2013-10-29 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
EP1743041B1 (en) 2004-05-03 2012-06-27 Stefan Kochanek Modified viral vector particles
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
WO2007084773A2 (en) * 2006-01-20 2007-07-26 University Of North Carolina At Chapel Hill Enhanced production of infectious parvovirus vectors in insect cells
EP2431469A3 (en) 2006-05-15 2012-05-30 Paratek Pharmaceuticals, Inc. Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
WO2008151219A1 (en) 2007-06-04 2008-12-11 Regeneron Pharmaceuticals, Inc. Enhanced expression and stability regions
US8852926B2 (en) 2007-10-25 2014-10-07 Board Of Trustees Of Southern Illinois University Genetic selection system for identification of MicroRNA target genes
DE102009003439A1 (de) 2009-02-05 2010-08-26 Cevec Pharmaceuticals Gmbh Neue permanente humane Zelllinie
WO2010138263A2 (en) * 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
US20130023033A1 (en) 2010-03-29 2013-01-24 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US9839696B2 (en) 2010-04-30 2017-12-12 City Of Hope Recombinant adeno-associated vectors for targeted treatment
SG187863A1 (en) 2010-08-16 2013-03-28 Cevec Pharmaceuticals Gmbh Permanent human amniocyte cell lines for producing influenza viruses
EP2662451A1 (en) 2012-05-07 2013-11-13 Stefan Kochanek Nucleic acid construct and use of the same
EP2711428A1 (en) 2012-09-21 2014-03-26 Lonza Biologics plc. Site-specific integration
ES2698610T3 (es) 2013-08-06 2019-02-05 Lonza Biologics Plc Medios y métodos para la generación de células productoras de mamífero para la producción de proteínas recombinantes
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
EP4410805A3 (en) 2014-03-18 2024-11-27 University of Massachusetts Raav-based compositions and methods for treating amyotrophic lateral sclerosis
KR102243243B1 (ko) 2014-10-23 2021-04-22 리제너론 파마슈티칼스 인코포레이티드 신규한 cho 통합 부위 및 이의 용도
EP3042952A1 (en) 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
TWI707951B (zh) 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造
EP3205719A1 (en) 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603577D0 (en) 2016-03-01 2016-04-13 Oxford Genetics Ltd Promoter
MX2018011928A (es) 2016-03-30 2019-03-28 Spark Therapeutics Inc Linea celular para produccion de proteina recombinante y/o vector viral.
US11512144B2 (en) 2016-04-20 2022-11-29 Regeneran Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing loci
GB2549809C (en) 2016-06-23 2022-11-30 Univ Oxford Innovation Ltd Vector
US20190171188A1 (en) 2016-08-10 2019-06-06 Lonza Inc. Biopharmaceutical Batch Recipe Review by Exception
JP7112414B2 (ja) 2017-02-08 2022-08-03 フリードリッヒ ミーシェー インスティトゥート フォー バイオメディカル リサーチ 網膜神経節細胞中の遺伝子の特異的発現のためのプロモーターｓｙｎｐ８８
WO2018150269A1 (en) 2017-02-17 2018-08-23 Lonza Ltd. Multi-site specific integration cells for difficult to express proteins
WO2018150271A1 (en) 2017-02-17 2018-08-23 Lonza Ltd. Mammalian cells for producing adeno-associated viruses
KR20190129092A (ko) 2017-03-17 2019-11-19 론자 리미티드 자동화된 배치 데이터 분석
JP7142643B2 (ja) 2017-03-22 2022-09-27 ウルトラジェニックス ファーマシューティカル インコーポレイテッド Ｈｄａｃ阻害剤またはｒｅｐタンパク質を伴う細胞培養方法
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
GB201705927D0 (en) 2017-04-12 2017-05-24 Oxford Genetics Ltd Vector
US10858631B2 (en) 2017-04-18 2020-12-08 Glaxosmithkline Intellectual Property Development Limited Methods for adeno-associated viral vector production
CN110892064A (zh) 2017-07-25 2020-03-17 牛津遗传学有限公司 腺病毒载体
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
EP3456822A1 (en) 2017-09-19 2019-03-20 CEVEC Pharmaceuticals GmbH Inducible aav rep genes
WO2019073059A1 (en) 2017-10-12 2019-04-18 Freeline Therapeutics Limited ADENOVIRAL AUXILIARY VIRUSES WITH DEFECTIVE CYCLE LIFE, PRODUCTION AND USE FOR THE PRODUCTION OF RAAV
JP7274225B2 (ja) 2017-10-25 2023-05-16 ノイスコム アーゲー 真核細胞系統
IL275462B2 (en) 2017-12-22 2026-01-01 Genentech Inc Targeted integration of nucleic acids
GB201800903D0 (en) 2018-01-19 2018-03-07 Oxford Genetics Ltd Vectors
WO2019157239A1 (en) 2018-02-08 2019-08-15 David Kiewlich Plasmid vectors for expression of large nucleic acid transgenes
GB201802122D0 (en) 2018-02-09 2018-03-28 Univ Oxford Innovation Ltd Product and use
GB201814590D0 (en) 2018-09-07 2018-10-24 Oxford Biomedica Ltd Viral vector production system
EP3597172A1 (en) 2018-07-16 2020-01-22 Kao Germany GmbH Hair treatment composition
WO2020041454A1 (en) 2018-08-21 2020-02-27 Lonza Ltd A process for creating reference data for predicting concentrations of quality attributes
GB201814141D0 (en) 2018-08-30 2018-10-17 Univ Oxford Innovation Ltd Method and compositions for producing a virus
JP7549582B2 (ja) 2018-10-01 2024-09-11 ロンザ リミテッド 予測可能かつ安定な導入遺伝子発現を有するｓｓｉ細胞および形成の方法
WO2020077411A1 (en) 2018-10-17 2020-04-23 Children's Medical Research Institute Nucleic acid molecules and methods for aav vector selection
GB201816919D0 (en) 2018-10-17 2018-11-28 Glaxosmithkline Ip Dev Ltd Adeno-associated viral vector producer cell lines
EP3870604B1 (en) 2018-10-26 2022-11-23 F. Hoffmann-La Roche AG Multispecific antibody screening method using recombinase mediated cassette exchange
KR20210108406A (ko) 2018-12-21 2021-09-02 론자 워커스빌 아이엔씨. 바이러스 벡터의 자동화된 생산
AU2019403279A1 (en) 2018-12-21 2021-07-01 Genentech, Inc. Targeted integration of nucleic acids
SG11202106217TA (en) * 2018-12-21 2021-07-29 Lonza Walkersville Inc Adeno-associated virus (aav) producer cell line and related methods
GB201901571D0 (en) 2019-02-05 2019-03-27 Oxford Genetics Ltd Inducible AAV sysyem
GB201902068D0 (en) 2019-02-14 2019-04-03 Cambridge Entpr Ltd Methods of reactivating proliferative capacity non-proliferative tissues
CN113544509A (zh) 2019-03-08 2021-10-22 牛津遗传学有限公司 选择抗体的方法
AU2020270960B2 (en) 2019-04-12 2026-01-29 Ultragenyx Pharmaceutical Inc. Engineered producer cell lines and methods of making and using the same
CA3138576A1 (en) 2019-05-16 2020-11-19 Trustees Of Boston University Regulated synthetic gene expression systems
AU2020284255A1 (en) 2019-05-30 2022-01-06 Solid Biosciences Inc. Recombinant herpesvirales vector
KR20220118436A (ko) 2019-12-19 2022-08-25 론자 워커스빌 아이엔씨. 바이러스 벡터의 자동화된 생산
WO2021146591A2 (en) 2020-01-17 2021-07-22 Asklepios Biopharmaceutical, Inc. Recombinant aav production
MX2022009560A (es) 2020-02-04 2022-09-09 Oxford Genetics Ltd Proceso de fabricacion de vectores virales adenoasociados.
GB202001484D0 (en) 2020-02-04 2020-03-18 Oxford Genetics Ltd DNA amplification method
JP2023518415A (ja) 2020-03-19 2023-05-01 ウルトラジェニックス ファーマシューティカル インコーポレイテッド 組換えａａｖにおいてｃａｐおよびｒｅｐ配列の逆パッケージングを低減するための組成物および方法
JP2023526348A (ja) 2020-05-15 2023-06-21 アイヴェックスソル インコーポレイテッド 細胞療法及び遺伝子療法のための安定したウイルスベクター産生細胞を産生するための組成物及び方法
CN113699147B (zh) 2020-05-22 2023-06-09 深圳市深研生物科技有限公司 基于四环素和Cumate的共调控序列
US20230279427A1 (en) 2020-07-24 2023-09-07 Regents Of The University Of Minnesota Cell lines for recombinant aav production and aav-implemented protein production
WO2022038367A1 (en) 2020-08-21 2022-02-24 Oxford Genetics Limited Process for making a recombinant aav library
GB202013057D0 (en) 2020-08-21 2020-10-07 Oxford Genetics Ltd Method of making recombinant aavs
GB202013060D0 (en) 2020-08-21 2020-10-07 Oxford Genetics Ltd Cell line
EP4006141A1 (en) 2020-11-25 2022-06-01 CEVEC Pharmaceuticals GmbH Method for the production of aav
WO2022173944A1 (en) 2021-02-11 2022-08-18 Lonza Houston, Inc. Adeno-associated virus (aav) production
WO2022223954A1 (en) 2021-04-19 2022-10-27 Oxford Genetics Limited Dna amplification method using care elements
US20230257831A1 (en) 2021-09-01 2023-08-17 Oxford Genetics Limited Method for determining aav titre
MX2024004691A (es) 2021-10-18 2024-05-23 Regeneron Pharma Transcripcion controlada de polinucleotidos.
CA3235566A1 (en) 2021-10-18 2023-04-27 Michael Goren Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites
WO2023173105A2 (en) 2022-03-10 2023-09-14 Saliogen Therapeutics, Inc. Tetracycline inducer/repressor system and simplified viral particle production

Also Published As

Publication number Publication date
CA3234939A1 (en) 2023-04-27
US20230193312A1 (en) 2023-06-22
EP4419696A1 (en) 2024-08-28
MX2024004647A (es) 2024-05-02
KR20240099288A (ko) 2024-06-28
AU2022373653A1 (en) 2024-05-02
US20250154524A1 (en) 2025-05-15
IL312124A (en) 2024-06-01
US12234472B2 (en) 2025-02-25
WO2023069926A1 (en) 2023-04-27
TW202323529A (zh) 2023-06-16
CN118103517A (zh) 2024-05-28

Similar Documents

Publication Publication Date Title
US9896665B2 (en) Proviral plasmids and production of recombinant adeno-associated virus
JP2022511348A (ja) Ａａｖトリプルプラスミドシステム
US12054738B2 (en) Stable cell lines for inducible production of rAAV virions
KR20240101596A (ko) 폴리뉴클레오티드의 제어된 전사
AU2022373655A1 (en) Mammalian cells comprising integrated cas9 genes to produce stable integration sites, and mammalian cells comprising stable integration sites and other sites
JP2024537896A (ja) アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞
JP2023546116A (ja) Ｖａ ｒｎａ転写のための核酸構築物
WO2025054007A9 (en) Genetic elements to increase recombinant aav production
US20250129127A1 (en) Systems for Amplification of AAV Rep and Cap Proteins
RU2818112C2 (ru) Нуклеиновая кислота, имеющая промоторную активность, и ее применение
US20250281640A1 (en) Nucleic acid having promoter activity and use thereof
WO2023212616A2 (en) Detection, quantification, and expression analysis of full viral capsids
HK40097144A (zh) 具有启动子活性的核酸及其用途
CN121794392A (zh) 用于产生aav的rep启动子
EA050453B1 (ru) Эукариотические клетки, содержащие аденовирус-ассоциированные вирусные полинуклеотиды
TW202405182A (zh) 生產重組ａａｖ顆粒之方法
KR20240050462A (ko) 항-aav 중화 항체의 검출 및 정량을 위한 신규 시스템
TW202311528A (zh) 大規模腺相關病毒產生系統
OA22010A (en) Nucleic Acid Having Promoter Activity And Use Thereof.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251016